About the Event
In 2021, roughly 1.9 million people were diagnosed with cancer in the United States. Yet, even with introduction of new checkpoint inhibitors just 20-40% of patients respond to immunotherapy. Kineta is on a mission to change that with a new monoclonal antibody designed to reverse immunosuppression and stimulate T Cells.
Join our webinar with Kineta CEO, Shawn Iodonato and President, Craig Phillips as they discuss the company’s upcoming clinical milestones including their agreement with Merck to evaluate KVA12123 in combination with KEYTRUDA® in patients with advanced solid tumors.